Potential of adaptive clinical trial designs in pharmacogenetic research

Pharmacogenomics

Volumn 13, Issue 5, 2012, Pages 571-578

  Van Der Baan, Frederieke H ^a,b   Knol, Mirjam J ^a,b   Klungel, Olaf H ^a,b   Egberts, Antoine Cg ^a,b   Grobbee, Diederick E ^a   Roes, Kit Cb ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

interim analysis; pharmacogenetics; pharmacogenomics; randomized controlled trial; study design

Indexed keywords

ANTIMIGRAINE AGENT; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MK 0674; PACLITAXEL; PLACEBO; TELCAGEPANT; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; EGFR GENE; GENE FUNCTION; GENE MUTATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MIGRAINE; MUTATIONAL ANALYSIS; OPTIMAL DRUG DOSE; PATIENT SELECTION; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; PROCESS MODEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; SOCIAL WELFARE; TREATMENT OUTCOME;

COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; ENDPOINT DETERMINATION; HUMANS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84859224484     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.10     Document Type: Review

References (22)

1. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development - an executive summary of the PhRMA Working Group. J. Biopharm. Stat. 16(3), 275-283 (2006).
2. Hung HM, O'Neill RT, Wang SJ, Lawrence J. A regulatory view on adaptive/flexible clinical trial design. Biom. J. 48(4), 565-573 (2006). (Pubitemid 44367896)
3. van der Baan FH, Klungel OH, Egberts AC et al. Pharmacogenetics in randomized controlled trials: considerations for trial design. Pharmacogenomics 12(10), 1485-1492 (2011).
4. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
5. Ho TW, Mannix LK, Fan X et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK0974, in acute treatment of migraine. Neurology 70(16), 1304-1312 (2008). (Pubitemid 351550355)
6. Giles FJ, Kantarjian HM, Cortes JE et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J. Clin. Oncol. 21(9), 1722-1727 (2003). (Pubitemid 46638583)
7. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatr. 9(5), 442-473 (2004). (Pubitemid 38903502)
8. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 50(4), 1029-1041 (1994).
9. Halperin M, Lan KK, Ware JH, Johnson NJ, DeMets DL. An aid to data monitoring in long-term clinical trials. Control Clin. Trials 3(4), 311-323 (1982). (Pubitemid 13113166)
10. Proschan MA, Lan KKG, Wittes JT. Statistical Monitoring of Clinical Trials. Springer, NY, USA (2006).
11. Lachin JM. A review of methods for futility stopping based on conditional power. Stat. Med. 24(18), 2747-2764 (2005). (Pubitemid 41358706)
12. van der Tweel I, van Noord PA. Early stopping in clinical trials and epidemiologic studies for 'futility': conditional power versus sequential analysis. J. Clin. Epidemiol. 56(7), 610-617 (2003). (Pubitemid 36960176)
13. Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebocontrolled trial. Am. J. Psychiatr. 159(8), 1361-1366 (2002). (Pubitemid 34832718)
14. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004). (Pubitemid 38637993)
15. Haber DA, Bell DW, Sordella R et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb. Symp. Quant. Biol. 70, 419-426 (2005). (Pubitemid 44124897)
16. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004). (Pubitemid 39209661)
17. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a Phase 3 placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24(31), 5034-5042 (2006). (Pubitemid 46631407)
18. Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized Phase 3 INTEREST trial. J. Clin. Oncol. 28(5), 744-752 (2010).
19. Wang SJ, Hung HM, O'Neill RT. Adaptive patient enrichment designs in therapeutic trials. Biom. J. 51(2), 358-374 (2009).
20. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 5(2), e45 (2008).
21. Rosenblum M, van der Laan MJ. Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. Biometrika 98(4), 845-860 (2011).
22. Bassler D, Briel M, Montori VM et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 303(12), 1180-1187 (2010).